Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Eftathios Kastritis, Nikolaos Kanellias, MD, Foteini Theodorakakou, MD, Erasmia Psimenou, MD, Charikleia Gakiopoulou, MD, Smaragdi Marinaki, Maria Roussou, MD, Maria Gavriatopoulou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1776.

https://doi.org/10.1182/blood-2019-126385

Published: 2019

Journal Articles

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Christopher P Venner, MD, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J White, MD, Andrew Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Marc Lalancette, MD FRCP, Martha L Louzada, MDMSc, Andrea Kew, MDFRCP(C), Arleigh McCurdy, MD, Tony Reiman, MD, Max Sherry, Gail T. McDonald, Bethany Elaine Monteith, MD, Engin Gul, BS, MBA, Bingshu E. Chen, Annette E. Hay

Blood (2019) 134 (Supplement_1): 1871.

https://doi.org/10.1182/blood-2019-122637

Published: 2019

Journal Articles

The Utilization of Screening Tests for Plasma Cell Dyscrasias By Internal Medicine Physicians at a Teaching Hospital

Omar Abughanimeh, MD, Ahmad Al-Shyoukh, Anahat Kaur, MD, Diala Alawneh, Soheila Hamidpour, Anuj Shrestha, MD, Sheshadri Madhusudhana, MD

Blood (2019) 134 (Supplement_1): 4732.

https://doi.org/10.1182/blood-2019-123077

Published: 2019

Journal Articles

Approximating International Myeloma Working Group Uniform Response Criteria to Derive Response for Multiple Myeloma (MM) Patients Using Data from Electronic Health Records (EHR)

Rebekah B. Foster, BA, Max Tromanhauser, BSE, Christopher Gayer, PhD, Patrick K. Gonzales, MS, Kathleen Maignan, NP, Adomah S. Opong, ANP, Aracelis Z. Torres, MPH, PhD, Kenneth R. Carson, MD PhD

Blood (2019) 134 (Supplement_1): 4727.

https://doi.org/10.1182/blood-2019-127181

Published: 2019

Journal Articles

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Poornima Ramadas, MBBS, Ajay Tambe, MBBS, Mijung Lee, MD

Blood (2019) 134 (Supplement_1): 5463.

https://doi.org/10.1182/blood-2019-131577

Published: 2019

Journal Articles

Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance

Vikram Premkumar, MD, Suzanne Lentzsch, MD PhD, Divaya Bhutani, MD

Blood (2019) 134 (Supplement_1): 3161.

https://doi.org/10.1182/blood-2019-123496

Published: 2019

Journal Articles

The Real-World Frequency of 24-Hour Urine Protein Electrophoresis (UPEP), Serum Free Light Chain (SFLC), and Serum Protein Electrophoresis (SPEP) Testing in Patients with Multiple Myeloma (MM)

Rebekah B. Foster, Nicole G. Lipitz, Aracelis Z. Torres, Kenneth R. Carson, MD PhD

Blood (2018) 132 (Supplement 1): 3536.

https://doi.org/10.1182/blood-2018-99-113508

Published: 2018

Journal Articles

Efficacy of Bortezomib Based Regimens and Disease Monitoring in Light Chain Multiple Myeloma: A Review of Literature

Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Shehroz Aslam, MD, Rida Riaz, MBBS, Seren Durer, MD, Ceren Durer, MD, Muhammad Abu Zar, MD, Zunairah Shah, MBBS, Ahmad Kamal, MD, Anum Qureshi, Jemin Aby Jose, MD, Insija Ilyas Selene, MBBS, Faiza Jamil, MD, Madeeha Shafqat, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5624.

https://doi.org/10.1182/blood-2018-99-109921

Published: 2018

Journal Articles

Epidemiological and Clinical Characteristics of Monoclonal Gammopathy of Renal Significance (MGRS) in South America

Camila Peña, MD, Gonzalo P Mendez, MD, Natalia Paola Schutz, MD, Eloisa Riva, MD, Ricardo Valjalo, MD, Hernán López-Vidal, MD, Alejandro Majlis, MD, Vivianne Lois, MD, Daniela Zamora, MD, Jose T Gonzalez, MD, Dorotea Beatriz Fantl, MD

Blood (2018) 132 (Supplement 1): 5856.

https://doi.org/10.1182/blood-2018-99-113198

Published: 2018

Journal Articles

The Gamma Gap: A Point-of-Care Test That Correlates with Disease Burden and Treatment Response in Multiple Myeloma

Megan Murray Dupuis, MD PhD, Zhiguo Li, PhD, Sascha A Tuchman, MD, Yubin Kang, MD

Blood (2017) 130 (Supplement 1): 4407.

https://doi.org/10.1182/blood.V130.Suppl_1.4407.4407

Published: 2017

Journal Articles

Monoclonal Gammopathies: Electronic Subspecialty Consultation

Nicholas Burwick, MD, Jacob Stein, David A Garcia, MD, Virginia C. Broudy, MD, Robert E. Richard, MD PhD

Blood (2017) 130 (Supplement 1): 673.

https://doi.org/10.1182/blood.V130.Suppl_1.673.673

Published: 2017

Journal Articles

Economic Model Shows That Guideline Recommended Testing of Patients with Early Symptoms of Myeloma Results in Improved Patient Outcomes and Decreased Hospital Costs

Elizabeth Wu, Ivar S Jensen, MBA, Philip Cyr, MPH, Harold Kisner

Blood (2017) 130 (Supplement 1): 4698.

https://doi.org/10.1182/blood.V130.Suppl_1.4698.4698

Published: 2017

Journal Articles

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Blood (2016) 128 (25): 2941–2948.

https://doi.org/10.1182/blood-2016-07-726778

Published: 2016

Journal Articles

Ruxolitinib Used to Treat Hypereosinophilic Syndrome

Seung Lee, bs, Coby Palmares, Niko Koutsoukos, J. Brice Weinberg, MD, Trisa Palmares, MD, Alice Song, MD, Harold Song, MD, Sheila Benedicto, bs, Michael Song, bs, Vu Phan, MD, Julia Song, MD

Blood (2016) 128 (22): 5500.

https://doi.org/10.1182/blood.V128.22.5500.5500

Published: 2016

Journal Articles

Serum Free Light Chain Responses Have Greater Concordance with Clinical Outcomes Than Those Assessed By Urine Electrophoresis in Light Chain Multiple Myeloma Patients

Thomas Dejoie, PharmD, Michel Attal, Philippe Moreau, Herve Avet-Loiseau, MD PhD

Blood (2016) 128 (22): 376.

https://doi.org/10.1182/blood.V128.22.376.376

Published: 2016

Journal Articles

Multiple Myeloma in Patients with HCV-Related Disease:a Case Report

Iolanda D. Vincelli, Patrizia Cufari, Francesco Di Raimondo, MD, Martino Massimo, Massimo Gentile, MD, Fortunato Morabito, Stefania Ciolli, Marco Rossi, MD, Francesca Ronco

Blood (2016) 128 (22): 5700.

https://doi.org/10.1182/blood.V128.22.5700.5700

Published: 2016

Journal Articles

Impact of Normalized Free Light Chain Ratio for Assessment of Monoclonal Protein in Patients with Light Chain Only and Oligosecretory Myeloma

Kentaro Narita, MD, Yoshiaki Usui, MD, Yoshiaki Abe, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2016) 128 (22): 2074.

https://doi.org/10.1182/blood.V128.22.2074.2074

Published: 2016

Journal Articles

Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria?

Eileen Boyle, Guillemette Fouquet, Julie Lejeune, Salomon Manier, MD, Lucile Musset, Claire Bories, Remy Dulery, MD, Stéphanie Guidez, Sarah Bonnet, Brigitte Onraed, Jean-Luc Faucompre, Sabine Tricot, Stephanie Poulain, Veronique Leblond, MD PhD, Kym Snell, Xavier Leleu, MD

Blood (2015) 126 (23): 3042.

https://doi.org/10.1182/blood.V126.23.3042.3042

Published: 2015

Journal Articles

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Lyubov Neglyad, Jennifer Bourke, RN, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, Kathleen Pogonowski, RN, Linda Tegnestam, RN, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4258.

https://doi.org/10.1182/blood.V126.23.4258.4258

Published: 2015

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Tomer M Mark, MD MSc, Angelique Boyer, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pogonowski, RN, Ekta Aneja, MD, Linda Tegnestam, RN, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4232.

https://doi.org/10.1182/blood.V126.23.4232.4232

Published: 2015

NARROW

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

The Utilization of Screening Tests for Plasma Cell Dyscrasias By Internal Medicine Physicians at a Teaching Hospital

Approximating International Myeloma Working Group Uniform Response Criteria to Derive Response for Multiple Myeloma (MM) Patients Using Data from Electronic Health Records (EHR)

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance

The Real-World Frequency of 24-Hour Urine Protein Electrophoresis (UPEP), Serum Free Light Chain (SFLC), and Serum Protein Electrophoresis (SPEP) Testing in Patients with Multiple Myeloma (MM)

Efficacy of Bortezomib Based Regimens and Disease Monitoring in Light Chain Multiple Myeloma: A Review of Literature

Epidemiological and Clinical Characteristics of Monoclonal Gammopathy of Renal Significance (MGRS) in South America

The Gamma Gap: A Point-of-Care Test That Correlates with Disease Burden and Treatment Response in Multiple Myeloma

Monoclonal Gammopathies: Electronic Subspecialty Consultation

Economic Model Shows That Guideline Recommended Testing of Patients with Early Symptoms of Myeloma Results in Improved Patient Outcomes and Decreased Hospital Costs

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Ruxolitinib Used to Treat Hypereosinophilic Syndrome

Serum Free Light Chain Responses Have Greater Concordance with Clinical Outcomes Than Those Assessed By Urine Electrophoresis in Light Chain Multiple Myeloma Patients

Multiple Myeloma in Patients with HCV-Related Disease:a Case Report

Impact of Normalized Free Light Chain Ratio for Assessment of Monoclonal Protein in Patients with Light Chain Only and Oligosecretory Myeloma

Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria?

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only